Mersana Therapeutics Inc., a Cambridge, Mass.-based developer of oncology agents, has raised $4 million in new convertible note funding, according to a regulatory filing. Listed backers include Fidelity Biosciences, Harris & Harris Group, PureTech Ventures, ProQuest Investments and Rho Ventures. The company had previously raised around $32 million. www.mersana.com
